The share price of Novacyt (LON: NCYT), the clinical diagnostics specialist and AIM’s top performer in 2020, tumbled 40% today on news that it is dispute with Department of Health and Social Care (DHSC).
Background
On 29 September 2020, Novacyt announced a second supply contract with the DHSC for its exsig®COVID-19 Direct kits and other products. In an earlier trading update on 29 January 2021, it explained it was in active discussions with the DHSC regarding an…
Sign up and read the full article
Register to continue reading our content.
Get FREE access now
Already a member? Login
Previous article
Next article
More on Novacyt SA
01/05/2025 · Company Insights
News covered here includes our assessment of excellent results from a provider of compliance and e-learning…
30/09/2022 · Company Insights
Having survived a near death experience several years ago, a manufacturer of specialist industrial equipment covered…
More Company Insights
Offers galore, but are they acceptable?
Order book is on the rise and it's looking more promising
Under-the-radar software company is looking good
More on Novacyt SA
More Company Insights